Neonatal care company Neola Medical has been granted a European patent for its core technology in continuous and non-invasive lung monitoring using gas absorption spectroscopy.

The patent strengthens the company's intellectual property protection in Europe, one of Neola's main markets, and complements recently granted patents in China and a pending application in the US.

"Europe is one of our main markets alongside the US, and the granted patent strengthens our strategic position in this important region. It further strengthens our intellectual property portfolio around our core medical technology for non-invasive lung monitoring and detection of lung complications," said Neola Medical's CEO Hanna Sjöström in a comment.

The new patent is the second in Neola's new patent family.